PR Oct 1, 2019
LineaRx’s iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer TrialPR Jul 1, 2019
LineaRx Receives Multiple Purchase Orders for Linear DNA for Use in Therapeutic DevelopmentPR May 21, 2019
LineaRx Anticipates Expansion in Diagnostics Market via Follow-on Order and New Linear DNA Amplicons for Additional AssaysPR Apr 29, 2019
LineaRx Achieves Higher Expression and Survival Rates in Human T Cells Transfected Non-Virally with Linear DNAPR Apr 8, 2019
Applied DNA Subsidiary LineaRx Achieves Biotech Industry First with Anti-CD19 Expression in Human CAR T Cells via Proprietary Non-Viral, Plasmid-Free PlatformPR Mar 1, 2019
Applied DNA Subsidiary LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine CandidatesPR Dec 4, 2018
LineaRx to Hold Analyst Day Webinar to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T TherapyPR Nov 7, 2018
Applied DNA Subsidiary LineaRx Provides Cost and Quality Advantages to Technogenetics Diagnostic SolutionsPR Oct 16, 2018
Applied DNA Subsidiary LineaRx Licenses CAR T Drug Candidate and Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing PlatformShow More